- Home
- ZBAI vs BLRX Comparison
ZBAI vs BLRX Comparison
Compare ZBAI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAI
- BLRX
- Stock Information
- Founded
- ZBAI 2015
- BLRX 2003
- Country
- ZBAI United States
- BLRX Israel
- Employees
- ZBAI N/A
- BLRX N/A
- Industry
- ZBAI Professional Services
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAI Consumer Discretionary
- BLRX Health Care
- Exchange
- ZBAI Nasdaq
- BLRX Nasdaq
- Market Cap
- ZBAI 17.3M
- BLRX 15.3M
- IPO Year
- ZBAI N/A
- BLRX 2011
- Fundamental
- Price
- ZBAI $0.32
- BLRX $4.45
- Analyst Decision
- ZBAI
- BLRX Strong Buy
- Analyst Count
- ZBAI 0
- BLRX 2
- Target Price
- ZBAI N/A
- BLRX $19.00
- AVG Volume (30 Days)
- ZBAI 2.4M
- BLRX 2.1M
- Earning Date
- ZBAI 06-06-2025
- BLRX 08-14-2025
- Dividend Yield
- ZBAI N/A
- BLRX N/A
- EPS Growth
- ZBAI N/A
- BLRX N/A
- EPS
- ZBAI N/A
- BLRX N/A
- Revenue
- ZBAI $720,000.00
- BLRX $22,340,000.00
- Revenue This Year
- ZBAI N/A
- BLRX N/A
- Revenue Next Year
- ZBAI N/A
- BLRX N/A
- P/E Ratio
- ZBAI N/A
- BLRX N/A
- Revenue Growth
- ZBAI 44.00
- BLRX 91.68
- 52 Week Low
- ZBAI $0.27
- BLRX $2.30
- 52 Week High
- ZBAI $2.50
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- ZBAI N/A
- BLRX 50.17
- Support Level
- ZBAI N/A
- BLRX $3.79
- Resistance Level
- ZBAI N/A
- BLRX $4.62
- Average True Range (ATR)
- ZBAI 0.00
- BLRX 0.56
- MACD
- ZBAI 0.00
- BLRX -0.13
- Stochastic Oscillator
- ZBAI 0.00
- BLRX 21.79
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.